Drug Comparison

PillID

Pill Identifier Drug Encyclopedia Drug Classes Compare Interactions Blog 🌙

Trulicity vs Ozempic

Trulicity (dulaglutide) and Ozempic (semaglutide) are both once-weekly injectable GLP-1 receptor agonists used to improve blood sugar control in adults with type 2 diabetes. Both have demonstrated cardiovascular benefits beyond glycemic control and have become central to modern diabetes management. Head-to-head clinical data show that semaglutide generally outperforms dulaglutide on both A1C reduction and weight loss, but both are valuable options with meaningful differences in clinical evidence, device design, and additional indications.

Quick Comparison

Feature	Dulaglutide (Trulicity)	Semaglutide (Ozempic)
Drug Class	GLP-1 receptor agonist	GLP-1 receptor agonist
Generic Name	Dulaglutide	Semaglutide
Brand Name	Trulicity	Ozempic (diabetes); Wegovy (obesity); Rybelsus (oral)
Approved For	Type 2 diabetes; CV risk reduction in T2D with CVD or multiple CV risk factors	Type 2 diabetes; CV risk reduction in T2D with CVD; obesity/overweight (Wegovy); CV risk reduction in non-diabetics with CVD (SELECT trial basis)
Available as Generic	No	No
Key Advantage	Simpler auto-injector device (hidden needle); REWIND trial CV benefit; broader CV risk factor eligibility	Greater A1C reduction and weight loss (~6kg vs ~3kg); approved for obesity (Wegovy); CV benefit in non-diabetics (SELECT trial); oral formulation available (Rybelsus)
Main Drawback	Less potent on A1C and weight vs semaglutide; no obesity approval; no oral option	More complex pen device; supply shortages have been a significant issue; higher price for Wegovy formulation

How They're Similar

Both drugs mimic the action of glucagon-like peptide-1 (GLP-1), an incretin hormone released after meals. They stimulate insulin secretion in a glucose-dependent manner, suppress glucagon, slow gastric emptying, and reduce appetite. Because insulin secretion is glucose-dependent, the risk of hypoglycemia is low when used without insulin or sulfonylureas.

Both are administered as once-weekly subcutaneous injections, both carry an FDA black box warning about thyroid C-cell tumors observed in rodent studies (clinical significance in humans is unclear but the warning exists for the class), and both are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2). GI side effects — nausea, vomiting, diarrhea, constipation — are the most common adverse effects for both and typically improve after the first few weeks.

Key Differences

Efficacy: Head-to-head data from the SUSTAIN 7 trial directly compared semaglutide 0.5 mg and 1 mg against dulaglutide 0.75 mg and 1.5 mg. Semaglutide achieved significantly greater reductions in A1C and body weight at both dose comparisons. Average weight loss with semaglutide in clinical trials is approximately 4–6 kg, compared to roughly 2–3 kg with dulaglutide. On A1C reduction, semaglutide consistently outperforms dulaglutide at comparable doses.

Cardiovascular outcome trials: The REWIND trial (dulaglutide) and the SUSTAIN-6 trial (semaglutide) both showed cardiovascular benefits. A key difference: REWIND enrolled patients with only multiple CV risk factors (not required to have established CVD) — one of the broadest CV outcome trial populations for a GLP-1. The SELECT trial for semaglutide showed CV benefit in non-diabetic patients with obesity and CVD, leading to a novel indication.

Obesity approval: Semaglutide at higher doses (Wegovy) is FDA-approved for chronic weight management in patients with obesity or overweight with a weight-related comorbidity. Dulaglutide has no obesity approval.

Device design: Trulicity uses a fixed-dose auto-injector with a hidden needle, which many patients find easier to use, particularly those with needle anxiety or dexterity limitations. Ozempic uses a multi-dose dial pen where the needle is visible after attachment.

Dulaglutide: Strengths & Weaknesses

Strengths: Hidden-needle auto-injector is highly user-friendly, broad CV outcome trial population (REWIND), generally adequate glycemic control for many patients, well-established safety data.

Weaknesses: Less potent than semaglutide on A1C and weight outcomes. No obesity indication. No oral formulation. Considered second-line to semaglutide by many prescribers when maximal efficacy is desired.

Semaglutide: Strengths & Weaknesses

Strengths: Superior A1C and weight reduction, obesity approval (Wegovy), CV benefit even in non-diabetics (SELECT), oral option (Rybelsus), most extensively studied GLP-1 in terms of outcome data breadth.

Weaknesses: Significant supply shortages have been an ongoing problem. More complex pen device. Wegovy pricing is substantially higher. GI side effects may be somewhat more pronounced at higher semaglutide doses.

Frequently Asked Questions